Medpace Holdings Inc vs Tripadvisor Inc Common Stock — how do they compare? Medpace Holdings Inc trades at $598 (market cap $16.90B), while Tripadvisor Inc Common Stock trades at $10.71 (market cap $1.28B). The key difference: Medpace Holdings Inc is far larger — about 13.2× Tripadvisor Inc Common Stock's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals.
| MEDP | TRIP | |
|---|---|---|
Market Cap | $16.90B | $1.28B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $19.14 |
52-Week Low | $393.42 | $9.24 |
Enterprise Value | $16.52B | $1.33B |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Tripadvisor (TRIP) trades at $10.695, down 0.79% on the day, reflecting persistent pressure from recent earnings misses and competitive challenges. The stock shows a bearish technical bias with weak moving averages, though oversold RSI levels hint at potential near-term support. Fundamentally, revenue growth is modest at $1.89B in 2025, but net margins remain thin at 0.27%, and a high P/E of 127.18 signals elevated expectations relative to earnings. The pending $700M sale of TheFork provides a liquidity boost but does not fully offset core business headwinds from AI-driven travel competition.
Outlook is cautious; while the stock trades below the consensus price target of $13.29, offering theoretical upside, investor sentiment is tempered by consecutive earnings misses and market share erosion. Key risks include stiff competition from AI travel tools, macroeconomic sensitivity, and execution challenges in revitalizing growth. Analysts are predominantly neutral (62.5% Hold), suggesting limited conviction in near-term catalysts despite the stock's current discount to target.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →